...
首页> 外文期刊>Hypertension research: Official journal of the Japanese Society of Hypertension >Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia
【24h】

Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia

机译:黄嘌呤氧化酶抑制剂对高血压高尿酸血症患者肾功能和血压的影响

获取原文
获取原文并翻译 | 示例

摘要

Hyperuricemia may promote the progression of hypertension and renal dysfunction. However, the effects of hyperuricemia treatment on blood pressure and renal function in adult hypertensive patients with hyperuricemia remain unclear. A total of 137 hypertensive patients with hyperuricemia (96 men and 41 women; mean age of 67 years) who recently started taking xanthine oxidase inhibitors (allopurinol or febuxostat) as outpatients were recruited. Serum uric acid level, estimated glomerular filtration rate (eGFR, ml min(-1) per 1.73 m(2)) and blood pressure (mm Hg) were retrospectively compared immediately before and shortly after starting treatment with xanthine oxidase inhibitors. The mean blood pressure and the eGFR immediately before starting treatment were 128/71 mm Hg and 44.6 ml min(-1) per 1.73 m(2), respectively. Although the eGFR decreased from 46.6 to 44.6 ml min(-1) per 1.73 m(2) before starting treatment with xanthine oxidase inhibitors, it increased to 46.2 ml min(-1) per 1.73 m(2) (P = 0.001, compared with immediately before treatment) without any significant changes in blood pressure after the administration of xanthine oxidase inhibitors. Multiple regression analysis revealed that the increase in eGFR after starting xanthine oxidase inhibitor treatment positively correlated with the changes in systolic blood pressure and negatively correlated with the changes in uric acid levels and the use of renin-angiotensin system inhibitors. These results suggest that xanthine oxidase inhibitors may delay the progression of renal dysfunction in adult hypertensive patients with hyperuricemia.
机译:高尿酸血症可促进高血压和肾功能不全的进展。然而,高尿酸血症治疗对成人高尿酸血症高血压患者的血压和肾功能的影响尚不清楚。总共招募了137例最近开始服用黄嘌呤氧化酶抑制剂(allopurinol或非布索坦)作为门诊患者的高尿酸血症高血压患者(男96例,女41例;平均年龄67岁)。在开始使用黄嘌呤氧化酶抑制剂治疗之前和之后不久,对血清尿酸水平,估计的肾小球滤过率(eGFR,ml min(-1)/1.73 m(2))和血压(mm Hg)进行回顾性比较。即将开始治疗前的平均血压和eGFR为1.73 m(2)分别为128/71 mm Hg和44.6 ml min(-1)。尽管开始用黄嘌呤氧化酶抑制剂治疗前eGFR从1.76 m(2)的46.6 ml min(-1)减少到1.73 m(2)的46.2 ml min(-1)(P = 0.001,相比在服用黄嘌呤氧化酶抑制剂后血压没有任何明显变化。多元回归分析显示,开始黄嘌呤氧化酶抑制剂治疗后eGFR的增加与收缩压的变化呈正相关,与尿酸水平的变化和肾素-血管紧张素系统抑制剂的使用呈负相关。这些结果表明,黄嘌呤氧化酶抑制剂可能会延迟成年高血压高尿酸血症患者肾功能障碍的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号